🔎 Trials Near Me

Utama › Kolitis Ulseratif › Alabama

Kajian klinikal Kolitis Ulseratif di Alabama

7 kajian untuk Kolitis Ulseratif sedang mencari peserta di lokasi di Alabama.

Bandar di Alabama

Teks kajian rasmi (Bahasa Inggeris)

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Digestive Health Specialists /ID# 280827, Dothan
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07697456

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Gastro Health, Birmingham
  • East View Medical Research, Mobile
Mengambil pesertaFasa 4
Umur 18 hingga 80 · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06581328

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Digestive Health Specialists, Dothan
Mengambil pesertaFasa 3
Umur 18 hingga 70 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06937086

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

  • Digestive Health Specialsits, Dothan
Mengambil pesertaFasa 4
Umur 18 hingga 65 · Semua jantina · Dikemas kini 21 Sep 2026 · NCT06095128

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • University of South Alabama (USA) Physicians Group, Mobile
Mengambil pesertaFasa 3
Umur 2 ke atas · Semua jantina · Dikemas kini 7 Mei 2026 · NCT05442567

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, Birmingham
Mengambil pesertaFasa 2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 12 Mac 2026 · NCT07113522

Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

  • University of Alabama Medicine, Birmingham
Mengambil peserta
Umur 18 hingga 85 · Semua jantina · Dikemas kini 8 Jan 2026 · NCT05987852

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.